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Myostatin, a member of the TGF- family, has been identified as a
powerful inhibitor of muscle growth. Absence or blockade of
myostatin induces massive skeletal muscle hypertrophy that is
widely attributed to proliferation of the population of muscle
fiber-associated satellite cells that have been identified as the
principle source of new muscle tissue during growth and regen-
eration. Postnatal blockade of myostatin has been proposed as a
basis for therapeutic strategies to combat muscle loss in genetic
and acquired myopathies. But this approach, according to the
accepted mechanism, would raise the threat of premature exhaus-
tion of the pool of satellite cells and eventual failure of muscle
regeneration. Here, we show that hypertrophy in the absence of
myostatin involves little or no input from satellite cells. Hypertro-
phic fibers contain no more myonuclei or satellite cells and myo-
statin had no significant effect on satellite cell proliferation in vitro,
while expression of myostatin receptors dropped to the limits of
detectability in postnatal satellite cells. Moreover, hypertrophy of
dystrophic muscle arising from myostatin blockade was achieved
without any apparent enhancement of contribution of myonuclei
from satellite cells. These findings contradict the accepted model of
myostatin-based control of size of postnatal muscle and reorient
fundamental investigations away from the mechanisms that con-
trol satellite cell proliferation and toward those that increase
myonuclear domain, by modulating synthesis and turnover of
structural muscle fiber proteins. It predicts too that any benefits of
myostatin blockade in chronic myopathies are unlikely to impose
any extra stress on the satellite cells.
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myonuclear domain
Loss of muscle mass and strength is a major clinical feature ofinherited myopathies such as Duchenne muscular dystrophy
(DMD) and also of more common acquired atrophies associated
with disuse, aging, and cancer. This loss has fostered widespread
interest in the powerful inhibitory effect of myostatin, a member
of the TGF- family of signalingmolecules, onmuscle growth (1)
with specific focus on the prospect of modulating this system to
counteract atrophic processes. Indeed, muscle fiber hypertrophy
arising from absence or blockade of myostatin has been reported
to be associated with therapeutic benefits in the mdx mouse
model of DMD (2, 3). This hypertrophy has been attributed to
proliferation of satellite cells (4, 5), the principal cellular source
for growing and regenerating skeletal muscle (6–10), conse-
quent upon their release from myostatin inhibition (5, 11, 12).
Here, we have investigated the contribution of satellite cells in
2 myostatin-null mouse models, constitutive (mstn/) and com-
pact (BEHc/c), and following myostatin blockade by AAV-
mediated overexpression of myostatin propeptide. These data,
together with our results from in vitro studies on the effect of
presence or absence of myostatin on satellite cells contradict
comprehensively the widely held view that postnatal muscle
hypertrophy elicited by the blockade or absence of myostatin is
the result of increased satellite cell activity.
Results
Lack of Myostatin Results Predominantly in Hypertrophy of Individual
Muscle Fibers. Having shown previously that mstn/ extensor
digitorum longus (EDL) muscles were 66% heavier than wild
type (13), we analyzed their cellular composition. They con-
tained only 11% more myofibers (P  0.026) than controls but
these myofibers were of 43% greater cross-sectional area (P 
0.003) and 6% longer (P  0.001; Table 1; Fig. 1). Similarly,
increased muscle size in the Berlin High mouse line compact
(BEHc/c), which harbors a naturally occurring mutation in the
myostatin gene (14, 15), reflects in part 37% more myofibers
(P  0.023) but, more importantly, a 93% larger mean fiber
cross-sectional area (P  0.001) and a significantly greater fiber
length (P  0.001) than BEH/ controls (supporting informa-
tion (SI) Table S1). Thus, the large size of myostatin-deficient
muscle is attributable chiefly to myofiber hypertrophy.
Muscle Fiber Hypertrophy Is Not Dependent on Satellite Cell Activity.
The number of myonuclei per myofiber reflects the cumulative
history of muscle precursor recruitment during fiber growth.
Surprisingly, EDL fibers of both mstn/ and BEHc/c mice
contained fewer myonuclei per fiber (P  0.001) than their
respective wild-type controls (Table 1; Table S1; Fig. 1). This
combination of larger size and fewer myonuclei must entail a
markedly higher cytoplasmic-to-nuclear ratio.
Such a pattern of myostatin-null-induced hypertrophy suggests
a lack of satellite cell recruitment. Immunostaining for Pax7,
which is expressed as a marker of both quiescent and activated
satellite cells (10), (Fig. 2A), we found fewer (P 0.001) satellite
cells per myofiber from mstn/ EDLs (3.2  2.3 SD) than on
equivalent wild-type myofibers (4.8  3.0 SD) (Table 1; Figs. 1
and 2), with similar observations in BEHc/c (P 0.001; Table S1).
Thus, the sustained muscle hypertrophy arising from lack of
myostatin is not associated with increase in either the number or
recruitment of satellite cells. (Counts in 2 other muscles con-
firmed the lack of satellite cell increase in mstn/ mice: soleus,
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wild type, 9.6  3.5, n  84; mstn/, 10.4  4.0, n  90; biceps
brachii, wild type, 3.9  2.1, n  64; mstn/, 3.1  1.9, n  65.)
Satellite Cell Proliferation Is Independent of Myostatin. To examine
the direct effect of myostatin on myoblast proliferation we
monitored the rate of increase in satellite cell numbers around
isolated myofibers in tissue culture growth medium. This con-
stitutes a biologically relevant model of the basic self-replacing
muscle unit, standardizing myoblast proliferation to the vari-
ability both in number and behavior of fiber-associated satellite
cells (16, 17), (Fig. 2B). After 72 h in culture, fewer myoblasts
(43  32 SD) had accumulated in cultures from 2-month-old
mstn/ mice than in those from age-matched wild-type mice
(58  35 SD; P  0.001; Fig. 3A). Although starting numbers of
cells per fiber were smaller in the former, the gradients, indi-
cating rates of increase in cell number, are indistinguishable.
Moreover, blockade of any potential contaminant myostatin in
the serum and chicken embryo extract with J16-mouse anti-
myostatin monoclonal antibody did not affect the number of
Table 1. Cellular morphometric properties of male Mstn/ and C57BL/6 wild-type EDL muscles
Variable Age (months) Mstn/ C57BL/6 wild type P*
Number of myofibers 7 1,200  71 (5) 1,083  65 (5) 0.026*
Fiber area (m2) 7 3,192  507 (5 mice, 974 fibers) 2,235  293 (6 mice, 1,251 fibers) 0.003*
Satellite cells per fiber 2 3.2  2.3 (212 fibers, 4 mice) 4.8  3.0 (272 fibers, 6 mice) 0.001*,**
Myonuclei per fiber 2 244.5  52 (212 fibers, 4 mice) 261.3  53 (244 fibers, 5 mice) 0.001*,**
Fiber length (m) 2 4,047  529 (89 fibers, 3 mice) 3,820  457 (117 fibers, 4 mice) 0.001*
Values are given as means together with standard deviation; number of muscles examined is given in parentheses. *, for statistical analysis unpaired t-test
and **, Kolmogorov-Smirnov 2-sample test were used and P below 0.05 considered as significant.
Fig. 1. Morphometric and cellular properties of EDL muscles from adult male
mstn/ mice compared to age-matched C57BL/6 wild types. (A) Total fiber
number of whole EDL muscles frommstn/mice (black column) compared to
wild types (gray column) (P  0.026). (B) EDL fiber area from Mstn/ mice
(black column) compared to wild types (gray column) (P 0.003). (C) Fiber size
distribution in the EDL from mstn/ mice (black diamonds) and wild-type
mice (white diamonds). (D) Number of myonuclei per isolated muscle fiber
from EDL muscles from mstn/ mice (black column) compared to wild types
(gray column) (P  0.001). (E) Number of Pax-7 positive satellite cells per
isolated muscle fiber from EDL muscles from mstn/ mice (black column)
compared to wild types (gray column) (P  0.001).
A
B
C
Fig. 2. Analysis of muscle fibers. (A) Part of an isolated fiber from wild-type
EDL, combined immunostaining against Pax-7 (green), and nuclear stain with
DAPI (blue). The image depicts 1 satellite cell (arrow) and numerous myonu-
clei. (B) Example of a culture of an isolated muscle fiber (arrow) from wild-type
EDL muscle after 3 days of in vitro incubation. Numerous myoblasts are present
in the proximity of the muscle fiber, which are visible as little dots at this
magnification in phase microscopy. (C) Immunostaining against revertant
fibers on a cross-section of EDL muscle from mstn/mdx mouse depicts 2
clusters of revertant fibers (3 and 13 revertant fibers, respectively, arrows) and
1 paler isolated revertant fiber (arrowhead).
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satellite cell progeny accumulating around mstn/ myofibers
(39  25 SD; P  0.228; Fig. 3A). Similarly, no difference in
myoblast accumulation was found between 1-year-old mstn/
and wild-type mice, with or without J16-antibody treatment
(data not shown).
For the complementary experiment, we exposed satellite cells
to recombinant myostatin, bioactivity of which was verified on
high-density cultures of limb bud mesenchyme (see SI Text).
Addition of 100 ng/mL recombinant myostatin to 2-day isolated
fiber cultures from wild-type EDL muscles had no effect on
myoblast proliferation over the subsequent 24 h (Fig. 3B).
Regression analysis of day 2 against day 3 values revealed a 5.5-
to 6-fold increase in number of myoblasts, requiring 2 cell
divisions over this 24-h period. So high a rate of proliferation,
lying toward the upper limit for mammalian cells, forms a
sensitive test for any inhibitory activities, rendering the lack of
effect of myostatin particularly impressive (Fig. 3C). We con-
clude that neither the presence nor the absence of myostatin has
any influence on satellite cell proliferation in vitro.
Myostatin Blockade in Adult Muscle Results in Satellite Cell Indepen-
dent Muscle Hypertrophy. Myostatin propeptide binds nonco-
valently to myostatin and inhibits its activity (18, 19). Induction
of this type of blockade in adult muscle, by injection of recom-
binant AAV-2/1 encoding the myostatin propeptide (AAV-
prop) yielded essentially the same results as mutations in the
myostatin gene. Injection of AAV-prop into the tibialis anterior
(TA) muscles of 2-month-old C57Bl6 mice induced a marked
weight increase compared with contralateral control TAmuscles
injected with AAV-2/1 encoding murine-secreted alkaline phos-
phatase (AAV-muSeAP). By 14 days the difference was 15%
(P  0.038), increasing by 28 days to 28% (P  0.001; Table 2);
thereafter, the weight did not increase significantly. Morpho-
metric analysis at 1 month revealed a 12% greater fiber area in
AAV-prop- than in AAV-muSeAP-treated controls, rising by 2
months to 16% (P  0.004; Table 2), reflecting a general shift
toward larger diameters but with no change in number of fiber
profiles (Table 2; Fig. S1). Myonuclear number per muscle fiber
profile in cross-sections was unchanged from controls by treat-
ment with AAV-prop vector (P  0.77); this was concordant
with a diminution of 24% in myonuclei per muscle total surface
area (P  0.031; Table 2). To examine the effect of myostatin
blockade on satellite cell number we injected AAV-prop into TA
muscles of Myf5nlacZ/ mice (20), in which nlacZ marks satellite
cells (21). One month later, no significant difference was ob-
served between AAV-prop and AAV-muSeAP-injected muscles
in the number of satellite cells per myofiber profile (P  0.31;
Table 2).
Postnatal Satellite Cells Downregulate Activin Receptors. Whereas
our data confirmed a recent demonstration that postnatal
myostatin blockade results in myofiber hypertrophy (22), we
found no evidence of accompanying satellite cell hyperactivity.
Seeking an explanatory mechanism for this finding, we assessed
the expression of the activin receptors of myostatin signaling,
AcvR2A and 2B, in muscle progenitors. Using a gfp reporter
gene targeted into the Pax3 locus (21) as an identifier, we were
able by FACS to obtain pure preparations of muscle progenitor
cells from embryonic (E13.5) and fetal (E17.5) (23) stages and
the predominant subset of satellite cells in postnatal (P12)
hypaxial trunk muscles (24). Real-time PCR analysis demon-
strated that while activin receptors are clearly expressed in
muscle progenitor cells from developmental stages, they were
barely detectable in postnatal satellite cells, in accord with the
latter’s obliviousness to myostatin blockade (Fig. 3D).
Myostatin Blockade Does Not Augment Muscle Regeneration in mdx
Mice. Next we reexamined the dystrophin-nullmdxmouse model
of DMD (25, 26) in which beneficial effects of lack or blockade
of myostatin have been reported (2, 3). EDL muscles from
constitutive mstn/mdx mice weighed 72% more (33 mg  1.7
SD) than those from mstn/mdx (19.2 mg  2.1 SD; P  0.001;
Table S2). They did contain 30% more fiber profiles/section,
although the large intersample variation rendered this nonsig-
nificant (P 0.078; Table S2). Fiber profile numbers are difficult
to interpret in mstn/mdx and mstn/mdx mice, being depen-
dent on the lengths and branching frequency of regenerated
fibers in addition to any putative increase in fiber number that
might be associated with the constitutive lack of myostatin.
Counts of Pax7 expressing satellite cells on EDL myofibers of
15-month-old mice revealed no significant difference between
mstn/mdx (11.8  5.67 SD) and mstn/mdx fibers (12.2 
6.18 SD) (P  0.44; Table S2), indicating no difference in the
satellite cell resource in the mstn/ environment.
In mouse muscle, persistence of centrally located myonuclei is
an indicator of previous regenerative activity. Muscle from
mstn/mdx mice and mstn/mdx mice showed no significant
difference in the frequency of such central nucleation of fibers
Fig. 3. Analysis of responsiveness of primary myoblasts to myostatin. (A)
Influence of myostatin on myoblast proliferation. Data are shown as cumu-
lative rank ogives of the numbers of myoblasts accumulating around isolated
fiber cultures from wild-type mice (green), mstn/ mice (red), and J16-
antibody-treated cultures of isolated fibers from mstn/ mice (blue). The
number of cells that had accumulated around each single myofiber during
72 h in tissue culture is plotted on the horizontal axis. The vertical axis is the
individual ranks, normalized to the rank total for each experiment to permit
comparison of data sets of different sample size. (B) Effect of myostatin on
growth of primary cultures of satellite cells from single myofibers isolated
from wild-type mice. After 2 days in culture, 100 ng/mL myostatin was added
to half of the cultures (full red squares) but not to the control group (full green
circles). The numbers of cells present 1 day later in each individual culture are
displayed as empty red squares for the myostatin-treated and open green
circles for the nontreated cultures, pairing the data for each culture between
days 2 and 3. (C) Plot of the data from B of the cell number present at day 2
against that in the same culture on day 3 in cultures treated with myostatin
(red squares) and in controls (green circles). The regression lines for myostatin-
treated cultures (red) and controls (green) are shown with mean square error
of prediction (R2) and regression equation that indicates the rate of cell
increase before and after treatment with myostatin. (D) Expression profiling
of activin receptors during muscle progenitor maturation. Real-time PCR
comparing of activin receptors 2 a and b expression in Pax3GFP/ muscle
progenitors during embryonic (E13.5), fetal (E17.5), and postnatal (P12)
stages. The relative levels of expression of activin receptors AcvR2A and
AcvR2B, shown normalized to MyoD expression, decrease dramatically be-
tween early development and the neonatal growth phase.
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(P 0.25; Table S2), again showing no effect of lack ofmyostatin
on mdx muscle regeneration.
As a further indicator of regenerative activity, we analyzed the
frequency of dystrophin-positive ‘‘revertant’’ fibers found spo-
radically in both mdx and DMD muscles (Fig. 2C). Progressive
expansion of revertant fiber clusters has been shown to be a
cumulative indicator of satellite cell-dependent muscle regener-
ation (27). Comparison of revertant fiber frequency in EDL
muscles from mstn/mdx mice and mstn/mdx mice revealed
no significant difference in total numbers, in numbers per
cluster, or the numbers of isolated revertant fibers (Table S2;
Fig. S2): further argument against any significant boost of net
regenerative activity of dystrophic muscle in the absence of
myostatin.
Discussion
Together, the above data comprehensively challenge the gener-
ally accepted mechanism of action of myostatin on satellite cells
in postnatal muscle. On the contrary, it attributes postnatal
muscle hypertrophy generated by lack of myostatin largely to
hypertrophy of individual fibers that owes little or nothing to
satellite cell activity, being generated mainly by increase in size
of the myonuclear domain. True, the larger number of fibers in
the genetically myostatin-null mice, especially in the BEHc/c
strain, does imply some excess proliferation of muscle progen-
itors during early muscle development. This accords with our
detection of expression of activin receptors at prenatal stages
and aligns with recent demonstrations that, during early myo-
genesis, myostatin acts to limit myogenic cell proliferation by
favoring their entry into terminal diffentiation (28). Even then,
the larger-than-normal size of muscle fibers in themyostatin-null
adults involved no increase in numbers of myonuclei per fiber,
implying some limiting influence other than myostatin on the
numbers of myogenic cells fusing into individual fibers over their
period of formation and growth. Moreover, blockade of myo-
statin in postnatal muscle produced no evidence for either de
novo generation of muscle fibers or for any increase in myonuclei
per myofiber profile. Furthermore, in the dystrophic mstn/
mdx mice, enhanced muscle growth was not attributable to an
increase above normal levels of muscle regeneration. This lack
of responsiveness of postnatal satellite cells to myostatin signal-
ing is explicable by their perinatal downregulation of activin
receptors.
Our in vitro data supporting this view are in agreement with
previous studies employing similar concentrations of myostatin
(29) but conflict with a previous publication employing 10- to
20-fold higher concentrations (4). The essentially artifactual
nature of tissue culture leaves open the debate as to what the
biologically appropriate doses and individual tissue culture
conditions are for evaluation of myostatin activity. However our
in vivo findings firmly contradict the notion that myostatin-
mediated control of satellite cell proliferation has any significant
influence on muscle fiber hypertrophy during normal postnatal
growth or during regeneration of dystrophic muscle. This reve-
lation points us away from the signaling pathways of satellite cell
activation and proliferation that are linked to the accepted view
of myostatin action (11), in both normal postnatal and regen-
erating myopathic muscle. It implicates, instead, mechanisms
whereby myostatin regulates protein balance within the muscle
fibers themselves. This accords well with recent biochemical
studies of muscle hypertrophy in myostatin null conditions (30,
31), finding little or no concordant increase in DNA content and
thus attributing much of the effect to enlargement of the
myonuclear domain, with associated increased transcription of
myofibrillar RNAs. A recent debate concluded that the rela-
tionship between muscle fiber hypertrophy and myonuclear
number was variable between models and situations (32). Our
data places the fiber hypertrophy associated with lack of myo-
statin activity at the extreme in which large size of muscle fibers
mainly reflects enlargement of myonuclear domain. It implies,
too, that this mechanism, rather than augmented satellite cell
activation, operates even in regenerating dystrophic muscle in
which satellite cells are actively proliferating in response to the
stimuli that mediate muscle repair.
From a practical viewpoint, we need to revise current views
that therapeutic strategies based on myostatin blockade coun-
teract muscle defects by stimulating satellite cell activity. Such an
adjustment does not conflict with a recent report on the effect
of myostatin blockade in adult muscular dystrophy patients,
which showed a tendency toward bigger muscle fibers with no
evidence of increased muscle regeneration (33). But the change
in rationale would usefully inform the design of future human
clinical trials of myostatin blockade such as those in DMD. The
implication that beneficial amounts of muscle hypertrophy are
independent of satellite cell activity raises the prospect of
combating forms of muscle weakness such as disuse atrophy that
are not directly associated with satellite cell function. It is
important, however, before further clinical trials, to explore the
consequences of an increased myonuclear domain on homeosta-
sis and physiological function of muscle tissue: specifically its
relationship to the severe decrease in specific force and the mito-
chondrial depletion observed in myostatin-deficient muscle (13).
Methods
Animals.Mstn/ founder breeding pairs on a C57BL/6 background were a gift
of Se-Jin Lee (Johns Hopkins University, Baltimore) (1). Myostatin knockout
Table 2. Morphometric properties after injection of AAV myostatin propeptide into tibialis anterior muscles compared to
AAV-MSeap injection
Variable Days postinjection AAV-prop AAV-MSeap P*
Muscle weight (mg) 14* 44.72  2.92 (6) 38.76  2.38 (6) 0.038
28* 50.10  2.77 (6) 39.05  0.55 (6) 0.0003
42* 51.55  2.40 (6) 40.12  1.49 (6) 0.00033
56* 49.98  4.32 (6) 39.05  0.97 (6) 0.002
70* 48.63  2.3 (6) 41.20  1.23 (6) 0.0021
Number of myofibers 28* 3,245.8  59.5 (5) 3,184.6  71.5 (5) 0.729
56* 3,328  131 (5) 3,420  72 (5) 0.47
Fiber area (m2) 28* 2,242  163 (16,035 fibers, 5 mice) 1,996  91 (16,238 fibers, 5 mice) 0.089
56* 2,156  41 (16,763 fibers, 5 mice) 1,865  116 (16,200 fibers, 5 mice) 0.004
Myonuclei per fiber 31** 0.65  0.06 (475 fibers, 4 mice) 0.63  0.07 (816 fibers, 4 mice) 0.774
Myonuclei/surface area (nE05/pixel) 31** 3.4  0.48 (4 mice) 4.5  0.38 (4 mice) 0.031
Myf5  ve cells/100 fibers 31* 3.2  2.5 (6 mice) 2.4  0.8 (6 mice) 0.31
AAV injections were performed into TA muscles of C57Bl6 mice at 8 weeks of age* or at 6 weeks of age**. Values are given as means together with standard
deviation; number of muscles examined is given in parentheses; for statistical analysis paired t-test was used and P  0.05 considered as significant.
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and wild-type mice (C57BL/6) were bred and kept in the animal facilities of The
Royal Veterinary College, London, under guidelines of the Home Office (UK)
under license PPL/70/5218.
Muscles from a subline of the Berlin High mouse line (BEH), which is
homozygous for the compact mutation (13–15, 34), were a kind gift from Lutz
Bunger. Muscles from 1.5-year-old male mstn/mdx mice and mstn/mdx
littermates were a kind gift from Kathryn Wagner (Johns Hopkins University,
Baltimore) (3). Myf5nlacZ/ mice (20) and Pax3GFP/ mice (21) were bred in the
animal facilities of the UMR-S 787, Medical Faculty Pitie´-Salpe´trie`re, under
institutional guidelines.
Production and Injection of AAV Vector. The myostatin propeptide construct
was prepared by PCR amplification of C57Bl6 cDNA and introduced into an
AAV-2-based vector under the control of the CMV promoter. The AAV-
muSeAP was described elsewhere (35). (Production details appear in support-
ing information.)
Single Fiber Isolation and Culture. EDL muscles were carefully dissected from
mice killed by cervical dislocation. Age and number of animals are given in
Tables 1 and 2; Tables S1 and S2. Myofibers isolated as described previously (36,
37) were either fixed in 4% PFA/PBS or cultured as detailed in SI Text (36, 37).
Immunohistochemistry of Single Muscle Fibers. Fixed myofibers were perme-
abilized with 0.5% (vol/vol) Triton X-100/PBS and blocked with 20% (vol/vol)
goat serum/PBS, as described previously (36). Satellite cells were visualized
with anti-Pax-7 antibody (DSHB) and Alexa Fluor 488 goat anti-mouse IgG
(Molecular Probes) before mounting in Faramount fluorescent mounting
medium (DakoCytomation) containing 100 ng/mL DAPI.
Morphometric Analysis of mstn/ and Compact Mice. EDL muscles were
weighed and then mounted in OCT (BDH) and frozen in melting isopentane
cooled in liquid nitrogen. Ten-micrometer transverse sections from the mid-
belly were cut on a cryostat and total number was counted in H&E-stained
transverse sections using Leica QWin software. Minimal and maximal fiber
diameters and fiber area of all fibers were determined using KS 300 software
(Carl Zeiss). Number and age of mice are given in Table 1 and Table S1.
Histological Analysis of AAV-Injected Muscles. After killing of AAV-injected
mice, both tibialis anterior muscles were removed, weighed, mounted in OCT,
and frozen in isopentane cooled in liquid nitrogen. Transverse cryostat sec-
tions (8m) were fixed in 2% paraformaldehyde for 30 min, blocked for 1 hour
in 1% BSA, 1% sheep serum, 0.1% triton X-100, and 0.001% sodium azide
before incubation with a rabbit anti-laminin antibody (Dako, Z0097, 1/300)
followed by Cy3-conjugated goat anti-rabbit IgG secondary antibody (Jackson
ImmunoResearch, 111–165-144, 1/200). After immunostaining for laminin,
fiber number, and CSA, and myonuclear number and position were analyzed
by Ellix software (Microvision).
LacZ-expressing nuclei were visualized in Myf5nlacZ/ mice and counted,
together with myonuclei, on 2 complete transverse cryostat sections (10 m)
of each AAV-injected TA muscle using standard protocols for X-Gal staining.
Most X-Gal positive nuclei were found adjacent to the sarcolemma and
designated satellite cells; the occasional X-Gal positive nucleus found within
muscle fibers, was not included in the satellite cell counts.
Real-Time Quantitative PCR. Real-Time PCR was performed according to stan-
dard protocols on a DNA Engine Opticon 2 System (Bio-Rad) as detailed in
supporting information.
FACS Sorting of Pax3 Positive Cells. Isolation and cell sorting of GFP cells were
performed as previously described (24). Expression of the receptors was
normalized toMyoD expression to make conservative allowance for the lower
frequency of activation of postnatal satellite cells.
Statistical Analysis. All values are expressed as mean standard deviation. To
determine significance between 2 groups, we made comparisons using the
unpaired Student’s t-tests and Kolmogorov-Smirnov 2-sample test for com-
parison of different mouse genotypes and paired Student’s t-tests for com-
parison of ipsilateral and contralateral muscles. P  0.05 was considered
statistically significant.
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